Clinical Trial Update: A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study evaluating LOAd703 in combination with atezolizumab for malignant melanoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• LOAd703

Snippet

Sponsor: Lokon Pharma AB | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-09-19